id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_nr3tsrvjhrhkjnmakmy6hwxcc4	Ferrán Catalá-López,	Does the development of new medicinal products in the European Union address global and regional health concerns?	2010	10	.pdf	application/pdf	7151	1017	54	Methods: We reviewed the information on new medicinal products approved by centralized procedure from 1995 between authorized medicinal products and burden of disease measures based on disability-adjusted life years Results: We considered 520 marketing authorizations for medicinal products and 338 active ingredients. DALYs and new medicinal product development (r = 0.619, p = 0.005) in the European Union, and a moderate Conclusions: We find that the development of new medicinal products is higher for some diseases than others. medicinal products changes with disease burden in different populations. We collected the following information: year of approval, name of the medicinal product, active ingredients (new chemical between human-use medicinal products authorized during the study period and burden of disease measures. development of medicinal products and disease burden From a public health perspective [18-20], the therapeutic value and degree of innovation of medicinal products could also be considered, referring to their	./cache/work_nr3tsrvjhrhkjnmakmy6hwxcc4.pdf	./txt/work_nr3tsrvjhrhkjnmakmy6hwxcc4.txt